Four Institutions Join Forces to Launch Bio AX Drug Development
AI TIMES ·
✦ AI Summary
According to AI TIMES, DGIST, Yuhan, Jeil InnoBioPharm, and the Yonsei-Yuhan Lung Cancer Research Institute signed a business agreement on A…
According to AI TIMES, DGIST, Yuhan, Jeil InnoBioPharm, and the Yonsei-Yuhan Lung Cancer Research Institute signed a business agreement on August 28 for joint research on AX in the bio industry and decided to build a cooperative framework that connects new drug development with clinical application. The agreement focuses on combining the four institutions' capabilities in AI and supercomputing, candidate substance discovery and development, and clinical research to link everything from identifying joint projects to verification and commercialization. They plan to operate a joint research organization and a steering council, combine technology and expertise from an AX perspective, and expand collaboration in a way that verifies development results in research, medical, and industrial settings. In particular, they highlighted their intention to expand industrial AX experience accumulated in the robotics and semiconductor sectors into biotech and create a new cooperation model. They also plan to turn unmet needs in the drug development process and clinical settings into concrete tasks together and build a structure that carries through from technology development to on-site application. Going forward, they intend to launch a tentatively named AX joint research lab and flesh out ways to use joint projects, data, and research infrastructure.
Perspective
This collaboration appears to be an effort to connect research, development, clinical work, and commercialization into a single flow, beyond simply having each institution hold its own technology. In biotech, for AX to lead to real results, the link between verification and on-site application is more important than technology development itself, and this plan seems to place emphasis on reducing that bottleneck. If results emerge, bio AX is likely to be seen not as a declarative form of collaboration, but as a change in how new drugs are developed.
This perspective is BizCrush's own commentary and is not part of the reporting by AI TIMES.
This article was produced with the help of an automated content generation algorithm.
Source: AI TIMES
View originalThis article was summarized and organized by BizCrush based on the original article from AI TIMES. For exact quotations and full details, please refer to the original article.